Skip to main content
. Author manuscript; available in PMC: 2011 Mar 15.
Published in final edited form as: J Immunol. 2010 Feb 17;184(6):3250–3259. doi: 10.4049/jimmunol.0900722

Figure 3. Phenotype of HSV-2 peptide-specific T cell responses measured by ICS and flow cytometry.

Figure 3

PBMC from 5 IS subjects were incubated with HSV-2 peptides deduced from IFN-γ ELISPOT as T cell epitopes in order to confirm the peptides and determine the phenotype of the responding T cells. PBMC from IS11 were incubated with DMSO only (A) or peptide UL19785-800 (B), PBMC from IS6 were incubated with DMSO only (C) or peptide UL4945-59 (D), PBMC from IS4 were incubated with DMSO only (E) or peptide ICP41001-1015 (F), PBMC from IS19 were incubated with DMSO only (G) or peptide UL39309-317 (H), and PBMC from IS2 were incubated with DMSO only (I) or peptide gD-2245-259 (J). The percentage of CD8+/IFN-γ+ (A-H) or CD4+/IFN-γ+ (I and J) T cells is displayed within each plot.